The Use of PARP Inhibitors in Cancer Therapy : Use as Adjuvant with Chemotherapy or Radiotherapy, Use as a Single Agent in Susceptible Patients, and Techniques Used to Identify Susceptible Patients
This chapter describes some of the techniques in use in our laboratories for the investigation of PARP inhibitors in clinical medicine. More specifically, we are involved in investigating the utility of PARP inhibitors in the treatment of hematopoietic malignancies. We are also actively investigating the properties of the PARP systems in cell biology. We begin the chapter with a very brief history of the invention and use of PARP inhibitors. We then explain the underlying logic of the use of PARP inhibitors either in combination with chemo- or radiotherapy or as single agents used alone. We then provide in full detail the protocols that we use to study PARP inhibitors in cell biology to identify patients that should be susceptible to PARP inhibitor treatment and to manage and investigate these patients throughout their treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:1608 |
|---|---|
| Enthalten in: |
Methods in molecular biology (Clifton, N.J.) - 1608(2017) vom: 20., Seite 343-370 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shall, Sydney [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adjuvants, Pharmaceutic |
|---|
| Anmerkungen: |
Date Completed 03.04.2018 Date Revised 22.06.2018 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1007/978-1-4939-6993-7_23 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM273718010 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM273718010 | ||
| 003 | DE-627 | ||
| 005 | 20231225001854.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/978-1-4939-6993-7_23 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0912.xml |
| 035 | |a (DE-627)NLM273718010 | ||
| 035 | |a (NLM)28695521 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shall, Sydney |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Use of PARP Inhibitors in Cancer Therapy |b Use as Adjuvant with Chemotherapy or Radiotherapy, Use as a Single Agent in Susceptible Patients, and Techniques Used to Identify Susceptible Patients |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.04.2018 | ||
| 500 | |a Date Revised 22.06.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a This chapter describes some of the techniques in use in our laboratories for the investigation of PARP inhibitors in clinical medicine. More specifically, we are involved in investigating the utility of PARP inhibitors in the treatment of hematopoietic malignancies. We are also actively investigating the properties of the PARP systems in cell biology. We begin the chapter with a very brief history of the invention and use of PARP inhibitors. We then explain the underlying logic of the use of PARP inhibitors either in combination with chemo- or radiotherapy or as single agents used alone. We then provide in full detail the protocols that we use to study PARP inhibitors in cell biology to identify patients that should be susceptible to PARP inhibitor treatment and to manage and investigate these patients throughout their treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a DNA repair | |
| 650 | 4 | |a Leukemia | |
| 650 | 4 | |a PARP | |
| 650 | 4 | |a PARP inhibitors | |
| 650 | 4 | |a Repair of double-strand DNA breaks | |
| 650 | 7 | |a Adjuvants, Pharmaceutic |2 NLM | |
| 650 | 7 | |a Poly(ADP-ribose) Polymerase Inhibitors |2 NLM | |
| 700 | 1 | |a Gaymes, Terry |e verfasserin |4 aut | |
| 700 | 1 | |a Farzaneh, Farzin |e verfasserin |4 aut | |
| 700 | 1 | |a Curtin, Nicola J |e verfasserin |4 aut | |
| 700 | 1 | |a Mufti, Ghulam J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Methods in molecular biology (Clifton, N.J.) |d 1984 |g 1608(2017) vom: 20., Seite 343-370 |w (DE-627)NLM074849794 |x 1940-6029 |7 nnns |
| 773 | 1 | 8 | |g volume:1608 |g year:2017 |g day:20 |g pages:343-370 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/978-1-4939-6993-7_23 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 1608 |j 2017 |b 20 |h 343-370 | ||